Sentences with word «myelogenous»

In 1972, she identified a genetic glitch in chronic myelogenous leukemia cells — a swap of genes she called chromosomal translocation — that resulted in the uncontrolled cell growth of cancer.

Joe Scott of Palm Beach Gardens, Fla., who was diagnosed with acute myelogenous leukemia in 2005, was told that there was a 20 per cent chance that the cancer would ever go into remission.

The vaccine fights myelogenous leukemia, which strikes 16,000 people a year, many of them senior citizens.

Adenine causes cell cycle arrest and autophagy of chronic myelogenous leukemia K562 cells via AMP - activated protein kinase signaling.

Antineoplastic mechanisms of niclosamide in acute myelogenous leukemia stem cells: inactivation of the NF - kappaB pathway and generation of reactive oxygen species.

Investigators report that the six - month study of nilotinib, a treatment for chronic myelogenous leukemia or CML, produced benefit for all study patients who completed the trial (11 of 12), with 11 patients reporting meaningful clinical improvements.

Stem cell transplants and new chemotherapy treatments have improved survival in acute myelogenous leukemia, which is relatively common in adults and the elderly.

Currently no treatment option is available for five percent of patients suffering from chronic myelogenous leukemia, since they have developed resistance to conventional medications.

A research group in Japan and in Korea has found a novel nutrient uptake process that maintains the activity of murine chronic myelogenous leukemia (CML) stem cells.

«How do harmful chronic myelogenous leukemia stem cells obtain their nutrients?.»

Temple University Hospital and Fox Chase Cancer Center are the only two sites in Philadelphia that participated in an international phase I, randomized clinical trial which tested the drug guadecitabine (SGI - 110) in Myelodysplastic syndromes (MDS) and acute myelogenous leukemia (AML).

Her research has recently shown that a signaling pathway dubbed «hedgehog» is important not only for normal development of stem cells but also for the growth of cancer cells in chronic myelogenous leukemia.

The team has shown that the microenvironment that controls hematopoietic stem cells can be targeted for the treatment of a set of disorders called myeloproliferative neoplasias, the most prominent of which are chronic myelomonocytic leukemia (CMML), juvenile myelomonocytic leukemia (JMML), and atypical chronic myelogenous leukemia (CML).

For example, chronic myelogenous leukemia is caused by overproduction of certain white blood cells in the bone marrow.

Cooper is leading a new nationwide clinical trial, conducted within the Children's Oncology Group (COG), for children and adolescents with relapsed acute myelogenous leukemia (AML) to test a drug, CPX - 351, which has been designed to kill leukemia cells while minimizing damage to the heart.

Already, a few examples exist — blood tests for hereditary colon cancer; the design of Herceptin, a breast cancer drug; and Gleevec, a drug used in chronic myelogenous leukemia — in which the identification of gene alterations translated into clinical applications.

Since the first targeted cancer therapy to treat chronic myelogenous leukemia became available in 2001, there has been an explosion in genomic technology.

In both acute and chronic myelogenous leukemia, immature white blood cells in the bone marrow multiply out of control.

Reinforcing the need to look beyond genomic alterations to understand the complexity of cancer, researchers from Dana - Farber / Boston Children's Cancer and Blood Disorders Center report that a normal enzyme called SYK pairs with FLT3, the most commonly mutated enzyme found in acute myelogenous leukemia (AML), to promote progression of the disease.

This knowledge laid the foundation for the targeted cancer treatment revolution inaugurated by imatinib (Gleevec ®), which has made another blood cancer, chronic myelogenous leukemia, a controllable, chronic disease for many patients.

Chronic myelogenous leukemia (CML) is a human disease associated with a consistent chromosomal translocation that results in sequences from the c - abl locus on chromosome 9 being fused to sequences in a breakpoint cluster region (bcr) on chromosome 22.

Recently, an HIV infected patient with acute myelogenous leukemia received a bone marrow transplant from a ccr5Δ32 homozygous donor [6].

The drug imatinib mesylate (Gleevec) is shown to be effective against chronic myelogenous leukemia (CML).

Dominique Bonnet and John E. Dick report the first conclusive evidence for cancer stem cells, identified in acute myelogenous leukemia (AML).

[3]-RRB- However, the presence of the Philadelphia (Ph) chromosome is not sufficiently specific to diagnose CML, since it is also found in acute lymphoblastic leukemia [4](aka ALL, 25 — 30 % of adult cases and 2 — 10 % of pediatric cases) and occasionally in acute myelogenous leukemia (AML).

New treatment strategies to overcome drug resistance in chronic myelogenous leukemia and other cancers will come from the detailed structure of the enzyme Abl.

A Phase I Study of DS - 3201B in Subjects with Acute Myelogenous Leukemia (AML) or Acute Lymphocytic Leukemia (ALL)

[8] p230 is usually associated with chronic myelogenous leukemia associated with neutrophilia and thrombocytosis.

• Subject has BCR - ABL - positive leukemia (chronic myelogenous leukemia in blast crisis).

Such fusions have been implicated in other cancers, notably chronic myelogenous leukemia (CML).

An exciting development in rational anticancer drug design is Gleevac, a drug that acts on a protein unique to the defective white blood cells in chronic myelogenous leukemia and on a related protein in a rare form of gastrointestinal cancer.

Immunodeficiency and chronic myelogenous leukemia - like syndrome in mice with a targeted mutation of the ICSBP gene.

There was scant experimental evidence for this hypothesis until 1994, when John Dick and colleagues demonstrated that leukemia - initiating stem cells (LSCs) present in the blood of leukemia patients may induce acute myelogenous leukemia (AML) when transplanted into severe combined immunodeficient mice (2).

May 30, 2015 Khoury et al ASCO AST - VAC1 Presentation Long - term Follow - up of Patients with Acute Myelogenous Leukemia Receiving an Autologous Telomerase - based Dendritic Cell Vaccine

Leukemia that starts in myeloid cells — the pathway that leads to red blood cells, platelets (cells that clot the blood), or white blood cells known as granulocytes — is called myeloid (or myelogenous / myeloblastic) leukemia.

Researchers at SciLifeLab has together with research physicians at Karolinska University Hospital and scientists at Heidelberg University identified a key player determining response to cytarabine — the most important drug against acute myelogenous leukemia.

Brian J. Druker, M.D. Oregon Health Sciences University Mechanism - based therapy for chronic myelogenous leukemia

City of Hope researchers may have discovered a more effective treatment for patients with chronic myelogenous leukemia (CML) according to a study published today in Nature Medicine.

During this time, she worked in the laboratory setting with MAPK signaling pathway in Chronic Myelogenous Leukemia, for which she received an American Society of Clinical Oncology (ASCO) Young Investigator Award.

Autologous HCT is used primarily for the treatment of diseases such as lymphoma, Hodgkin disease, acute myelogenous leukemia, myeloma, breast cancer and testicular cancer.

It is used to treat chronic phase and accelerated phase Philadelphia chromosome positive chronic myelogenous leukemia (Ph + CML).

Gene - based therapy targets the FLT - 3 gene, the culprit in a lethal form of acute myelogenous leukemia.

In support of the first tenet, both chronic myelogenous leukemia (11) and acute myelogenous leukemia (12) seem to have arisen from the committed progenitor cells that have acquired self - renewing capabilities.